Regado Biosciences Inc (RGDO) 2.94 $RGDO
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Regado Biosciences, Inc. to Contact Brower Piven Before the September 8, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- RGDO
GlobeNewswire - Wed Jul 30, 4:01PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Regado Biosciences, Inc. ("Regado" or the "Company"
(Nasdaq:RGDO) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about August 21, 2013, or on the open market between August 22, 2013 and July 2, 2014, inclusive (the "Class Period" .
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights
PR Newswire - Tue Jul 29, 3:10PM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that it will hold a conference call and live audio webcast on Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to discuss its second quarter 2014 financial results and corporate highlights.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Regado Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline -- RGDO
GlobeNewswire - Fri Jul 25, 4:58PM CDT
Pomerantz LLP has filed a class action lawsuit against Regado Biosciences, Inc. ("Regado" or the "Company" (Nasdaq:RGDO) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-04345-JAP-DEA, is on behalf of a class consisting of all persons or entities who purchased Regado securities between August 22, 2013 and July 9, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Regado Biosciences, Inc. to Contact Brower Piven Before the September 8, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Jul 22, 5:21PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Regado Biosciences, Inc. ("Regado" or the "Company" (NASDAQ:RGDO) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about August 21, 2013, or on the open market between August 22, 2013 and July 2, 2014, inclusive (the "Class Period" .
Wolf Haldenstein Adler Freeman & Herz LLP Announces that a Class Action Lawsuit on Behalf of Regado Biosciences, Inc. Investors Has Been Filed -- RGDO
GlobeNewswire - Mon Jul 21, 4:17PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Regado Biosciences, Inc. ("Regado" or the "Company" (Nasdaq:RGDO) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on August 21, 2013, the secondary public offering on April 11, 2014, or on the open market between August 22, 2013 and July 2, 2014, inclusive (the "Class Period" .
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Fri Jul 18, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Regado Biosciences, Inc. -- RGDO
GlobeNewswire - Wed Jul 16, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court, District of New Jersey on behalf of all persons who purchased or otherwise acquired the securities of Regado Biosciences, Inc. ("Regado" or the "Company" (Nasdaq:RGDO) during the period between August 22, 2013 and July 9, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Regado Biosciences, Inc. -- RGDO
GlobeNewswire - Wed Jul 16, 3:52AM CDT
The Rosen Law Firm announced today that a class action lawsuit has been filed on behalf of all purchasers of Regado (Nasdaq:RGDO) securities pursuant and/or traceable to the Company's initial public offering that commenced on or after August 21, 2013 ("IPO" , including open market purchasers between August 22, 2013 and July 2, 2014, seeking to recover investors' losses.
Harwood Feffer LLP Announces Investigation of Regado Biosciences, Inc.
PR Newswire - Tue Jul 15, 8:00PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Regado Biosciences, Inc. ("Regado" or the "Company" (NASDAQ: RGDO) concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.
INVESTOR ALERT: Class Action Lawsuit Against Regado Biosciences, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Jul 15, 7:32AM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all purchasers of the securities of Regado Biosciences, Inc. ("Regado" or the "Company" (NASDAQ:RGDO) pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about August 21, 2013, or on the open market between August 22, 2013 and July 2, 2014, inclusive (the "Class Period" .
Attention Regado Biosciences, Inc. Investors: Regado Misled Investors According to a Recently Filed Class Action
PR Newswire - Mon Jul 14, 4:37PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Regado Biosciences, Inc. (NASDAQ: RGDO) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between August 22, 2013 and July 9, 2014 (the "Class Period" . Regado is a biopharmaceutical company that focuses on the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular and other indications.
INVESTOR ALERT: Class Action Lawsuit Against Regado Biosciences, Inc. Filed by Glancy Binkow & Goldberg LLP
Business Wire - Fri Jul 11, 1:43PM CDT
Glancy Binkow & Goldberg LLP, representing investors of Regado Biosciences, Inc. ("Regado" or the "Company" (NASDAQ:RGDO), has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of a class (the "Class" comprising all purchasers of Regado securities pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about August 21, 2013, or on the open market between August 22, 2013 and July 2, 2014, inclusive (the "Class Period" .
Pomerantz Law Firm Announces the Filing of a Class Action Against Regado Biosciences, Inc. and Certain Officers -- RGDO
GlobeNewswire - Thu Jul 10, 7:38PM CDT
Pomerantz LLP has filed a class action lawsuit against Regado Biosciences, Inc. ("Regado" or the "Company" (Nasdaq:RGDO) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-04345-JAP-DEA, is on behalf of a class consisting of all persons or entities who purchased Regado securities between August 22, 2013 and July 9, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
Regado's REGULATE-PCI Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:30PM CDT
The FDA has placed a clinical hold on patient enrollment and dosing in Regado Biosciences, Inc.'s (RGDO) ongoing phase III REGULATE-PCI study.
Regado Biosciences Announces Clinical Hold of REGULATE-PCI Trial Following Voluntary Halt of Trial by Regado
PR Newswire - Wed Jul 09, 3:05PM CDT
Regado Biosciences, Inc., (NASDAQ: RGDO) today announced that, further to their decision to voluntarily pause enrollment in their REGULATE-PCI trial, the United States Food and Drug Administration (FDA) informed the company today that a clinical hold has been placed on all patient enrollment and dosing of either study drug in the ongoing Phase 3 REGULATE-PCI trial. According to the FDA, this action was taken to formalize the involvement of the FDA in any decision to re-initiate enrollment and dosing in the trial in the future.
Biotech Stock Roundup: Regado Plunges on Study Update, Jazz Gains on Product Acquisition Deal - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 09, 8:15AM CDT
Regado was a big loser last week with the company announcing that an unplanned data review by a Data Safety Monitoring Board (DSMB) is being conducted for a late-stage study on lead pipeline candidate.
Regado Slumps on Revolixys Study Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 4:10PM CDT
Regado (RGDO) shares nosedived a massive 53.43% last week after its phase III study on Revolixys Kit was halted.
SHAREHOLDER ALERT: Investigation on Behalf of Regado Biosciences, Inc. Investors Announced by Law Offices of Howard G. Smith
Business Wire - Mon Jul 07, 12:32PM CDT
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Regado Biosciences, Inc. ("Regado" or the "Company" (NASDAQ:RGDO). The investigation concerns possible violations of federal securities laws and focuses on the Company's operations and financial prospects.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Regado Biosciences, Inc. to Contact Brower Piven Before the September 8, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- RGDO
GlobeNewswire - Wed Jul 30, 4:01PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Regado Biosciences, Inc. ("Regado" or the "Company"
(Nasdaq:RGDO) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about August 21, 2013, or on the open market between August 22, 2013 and July 2, 2014, inclusive (the "Class Period" . 3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights
PR Newswire - Tue Jul 29, 3:10PM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that it will hold a conference call and live audio webcast on Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to discuss its second quarter 2014 financial results and corporate highlights.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Regado Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline -- RGDO
GlobeNewswire - Fri Jul 25, 4:58PM CDT
Pomerantz LLP has filed a class action lawsuit against Regado Biosciences, Inc. ("Regado" or the "Company"
(Nasdaq:RGDO) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-04345-JAP-DEA, is on behalf of a class consisting of all persons or entities who purchased Regado securities between August 22, 2013 and July 9, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Regado Biosciences, Inc. to Contact Brower Piven Before the September 8, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Jul 22, 5:21PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Regado Biosciences, Inc. ("Regado" or the "Company"
(NASDAQ:RGDO) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about August 21, 2013, or on the open market between August 22, 2013 and July 2, 2014, inclusive (the "Class Period" . Wolf Haldenstein Adler Freeman & Herz LLP Announces that a Class Action Lawsuit on Behalf of Regado Biosciences, Inc. Investors Has Been Filed -- RGDO
GlobeNewswire - Mon Jul 21, 4:17PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Regado Biosciences, Inc. ("Regado" or the "Company"
(Nasdaq:RGDO) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on August 21, 2013, the secondary public offering on April 11, 2014, or on the open market between August 22, 2013 and July 2, 2014, inclusive (the "Class Period" . Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Fri Jul 18, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Regado Biosciences, Inc. -- RGDO
GlobeNewswire - Wed Jul 16, 6:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court, District of New Jersey on behalf of all persons who purchased or otherwise acquired the securities of Regado Biosciences, Inc. ("Regado" or the "Company"
(Nasdaq:RGDO) during the period between August 22, 2013 and July 9, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Regado Biosciences, Inc. -- RGDO
GlobeNewswire - Wed Jul 16, 3:52AM CDT
The Rosen Law Firm announced today that a class action lawsuit has been filed on behalf of all purchasers of Regado (Nasdaq:RGDO) securities pursuant and/or traceable to the Company's initial public offering that commenced on or after August 21, 2013 ("IPO"
, including open market purchasers between August 22, 2013 and July 2, 2014, seeking to recover investors' losses. Harwood Feffer LLP Announces Investigation of Regado Biosciences, Inc.
PR Newswire - Tue Jul 15, 8:00PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Regado Biosciences, Inc. ("Regado" or the "Company"
(NASDAQ: RGDO) concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws. INVESTOR ALERT: Class Action Lawsuit Against Regado Biosciences, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Jul 15, 7:32AM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all purchasers of the securities of Regado Biosciences, Inc. ("Regado" or the "Company"
(NASDAQ:RGDO) pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about August 21, 2013, or on the open market between August 22, 2013 and July 2, 2014, inclusive (the "Class Period" . Attention Regado Biosciences, Inc. Investors: Regado Misled Investors According to a Recently Filed Class Action
PR Newswire - Mon Jul 14, 4:37PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Regado Biosciences, Inc. (NASDAQ: RGDO) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between August 22, 2013 and July 9, 2014 (the "Class Period"
. Regado is a biopharmaceutical company that focuses on the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular and other indications. INVESTOR ALERT: Class Action Lawsuit Against Regado Biosciences, Inc. Filed by Glancy Binkow & Goldberg LLP
Business Wire - Fri Jul 11, 1:43PM CDT
Glancy Binkow & Goldberg LLP, representing investors of Regado Biosciences, Inc. ("Regado" or the "Company"
(NASDAQ:RGDO), has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of a class (the "Class" comprising all purchasers of Regado securities pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about August 21, 2013, or on the open market between August 22, 2013 and July 2, 2014, inclusive (the "Class Period" . Pomerantz Law Firm Announces the Filing of a Class Action Against Regado Biosciences, Inc. and Certain Officers -- RGDO
GlobeNewswire - Thu Jul 10, 7:38PM CDT
Pomerantz LLP has filed a class action lawsuit against Regado Biosciences, Inc. ("Regado" or the "Company"
(Nasdaq:RGDO) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-04345-JAP-DEA, is on behalf of a class consisting of all persons or entities who purchased Regado securities between August 22, 2013 and July 9, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . Regado's REGULATE-PCI Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 5:30PM CDT
The FDA has placed a clinical hold on patient enrollment and dosing in Regado Biosciences, Inc.'s (RGDO) ongoing phase III REGULATE-PCI study.
Regado Biosciences Announces Clinical Hold of REGULATE-PCI Trial Following Voluntary Halt of Trial by Regado
PR Newswire - Wed Jul 09, 3:05PM CDT
Regado Biosciences, Inc., (NASDAQ: RGDO) today announced that, further to their decision to voluntarily pause enrollment in their REGULATE-PCI trial, the United States Food and Drug Administration (FDA) informed the company today that a clinical hold has been placed on all patient enrollment and dosing of either study drug in the ongoing Phase 3 REGULATE-PCI trial. According to the FDA, this action was taken to formalize the involvement of the FDA in any decision to re-initiate enrollment and dosing in the trial in the future.
Biotech Stock Roundup: Regado Plunges on Study Update, Jazz Gains on Product Acquisition Deal - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 09, 8:15AM CDT
Regado was a big loser last week with the company announcing that an unplanned data review by a Data Safety Monitoring Board (DSMB) is being conducted for a late-stage study on lead pipeline candidate.
Regado Slumps on Revolixys Study Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 4:10PM CDT
Regado (RGDO) shares nosedived a massive 53.43% last week after its phase III study on Revolixys Kit was halted.
SHAREHOLDER ALERT: Investigation on Behalf of Regado Biosciences, Inc. Investors Announced by Law Offices of Howard G. Smith
Business Wire - Mon Jul 07, 12:32PM CDT
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Regado Biosciences, Inc. ("Regado" or the "Company"
(NASDAQ:RGDO). The investigation concerns possible violations of federal securities laws and focuses on the Company's operations and financial prospects. 
